title: Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of using cabergoline for reducing the risk of ovarian hyperstimulation syndrome (OHSS).
  
  
  METHODS
  Systematic review and meta-analysis of randomized clinical trials (RCTs).
  
  
  METHODS
  Women submitted to controlled ovarian stimulation (COS) for assisted reproduction.
  
  
  METHODS
  Cabergoline.
  
  
  METHODS
  Fertility centers.
  
  
  METHODS
  Moderate-severe OHSS, live birth, clinical pregnancy, number of retrieved oocytes, miscarriage, congenital abnormalities. Comparisons were performed with the use of risk ratios (RRs) or mean differences (MDs) and their respective 95% confidence intervals (CIs).
  
  
  RESULTS
  Eight RCTs were considered to be eligible; data from seven studies could be extracted and included in the meta-analysis. Cabergoline reduces the risk of moderate-severe OHSS (RR 0.38, 95% CI 0.29-0.51, 7 studies, 858 women) and probably has no clinically relevant negative impact on clinical pregnancy (RR 1.02, 95% CI 0.78-1.34, 4 studies, 561 women) or on the number of retrieved oocytes (MD 1.15, 95% CI -0.76 to 3.07, 5 studies, 628 women). However, our estimates were imprecise for distinguishing between substantial harm, no effect, and substantial benefit considering live birth (RR 1.03, 95% CI 0.71-1.48, 1 study, 200 women), and miscarriage (RR 0.69, 95% CI 0.27 to 1.76, 3 studies, 194 pregnant women). No studies reported congenital abnormalities.
  
  
  CONCLUSIONS
  Cabergoline reduces the occurrence of moderate-severe OHSS. Cabergoline is unlikely to have a clinically relevant negative impact on clinical pregnancy or on the number of retrieved oocytes. However, we are still uncertain of its impact on live birth, miscarriage, and congenital abnormalities.
authors.affiliation: Department of Obstetrics and Gynecology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
authors.forename: Valeria M S
authors.initials: VM
authors.lastname: Leitao
authors.affiliation: Department of Obstetrics and Gynecology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
authors.forename: Rafael M
authors.initials: RM
authors.lastname: Moroni
authors.affiliation: Department of Obstetrics and Gynecology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
authors.forename: Ludimila M D
authors.initials: LM
authors.lastname: Seko
authors.affiliation: Department of Obstetrics and Gynecology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirao Preto, São Paulo, Brazil; Ultrasonography and Retraining Medical School of Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil.
authors.forename: Carolina O
authors.initials: CO
authors.lastname: Nastri
authors.affiliation: Department of Obstetrics and Gynecology, Medical School of Ribeirão Preto, University of São Paulo, Ribeirao Preto, São Paulo, Brazil; Ultrasonography and Retraining Medical School of Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil. Electronic address: wpmartins@gmail.com.
authors.forename: Wellington P
authors.initials: WP
authors.lastname: Martins
mesh_terms: D000077465:Cabergoline; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054315:Oocyte Retrieval / Q000379:methods; D016471:Ovarian Hyperstimulation Syndrome / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D027724:Reproductive Techniques, Assisted
chemical_list: D004873:Ergolines; D000077465:Cabergoline
keywords: Cabergoline; assisted reproductive techniques; ovarian hyperstimulation syndrome; ovulation induction; review